# Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update
Canonical URL: https://biopharmsignal.com/news/EXEL/exelixis-announces-fourth-quarter-and-fiscal-year-2025-financial-results-and-provides-corporate-update
Ticker: EXEL
Company: Exelixis
Source: Exelixis
Published: 2026-02-10 21:05 EST
Original Source URL: https://ir.exelixis.com
## Summary

–   Total Revenues of $599 million for the Fourth Quarter of 2025, $2.320 billion for the Fiscal Year 2025 – –   Cabozantinib Franchise Achieved $2.123 billion   in U.S. Net Product Revenues for the Fiscal Year 2025, including $547 million for the Fourth Quarter of 2025 – – GAAP Diluted EPS of

## Article Body
–   Total Revenues of $599 million for the Fourth Quarter of 2025, $2.320 billion for the Fiscal Year 2025 – –   Cabozantinib Franchise Achieved $2.123 billion   in U.S. Net Product Revenues for the Fiscal Year 2025, including $547 million for the Fourth Quarter of 2025 – – GAAP Diluted EPS of
## Recent Company News
- 2026-05-30 14:00 EST — [Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026](https://biopharmsignal.com/news/EXEL/exelixis-announces-results-from-subgroup-analysis-of-phase-3-cabinet-pivotal-trial-evaluating-cabometyxr-cabozantinib-in-non-functional-and-functional-neuroendocrine-tumors-at-asco-2026) — Source: Exelixis
- 2026-05-27 20:05 EST — [Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June](https://biopharmsignal.com/news/EXEL/exelixis-to-webcast-fireside-chats-as-part-of-upcoming-investor-conferences-in-june) — Source: Exelixis
- 2026-05-21 21:00 EST — [Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types](https://biopharmsignal.com/news/EXEL/exelixis-announces-presentations-at-asco-2026-highlighting-ongoing-studies-in-diverse-tumor-types) — Source: Exelixis
- 2026-05-19 12:00 EST — [Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer](https://biopharmsignal.com/news/EXEL/exelixis-announces-clinical-development-collaboration-with-merck-for-phase-3-stellar-316-pivotal-trial-for-patients-with-colorectal-cancer) — Source: Exelixis
- 2026-05-07 20:05 EST — [Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May](https://biopharmsignal.com/news/EXEL/exelixis-to-webcast-fireside-chats-as-part-of-upcoming-investor-conferences-in-may) — Source: Exelixis
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)